Table 1 Demographics and clinical response according to randomized treatment
|  | All patients n = 36 | Randomized treatment |  | ||
|---|---|---|---|---|---|
Paroxetine n = 18 | Clomipramine n = 9 | Placebo n = 9 | Statistical significance | ||
Sex, males/females, n (% males) | 17/19 (47) | 8/10 (44) | 7/2 (78) | 2/7 (22) | ns |
Age, years | 40.7 ± 12.7 | 38.7 ± 11.8 | 41.0 ± 13.5 | 44.6 ± 14.3 | ns |
OCD, age of onset, years | 14.5 ± 6.5 | 15.2 ± 5.1 | 13.3 ± 8.7 | 14.2 ± 7.3 | ns |
OCD duration, years | 26.2 ± 14.8 | 23.4 ± 13.7 | 27.6 ± 15.3 | 30.3 ± 16.8 | ns |
Y-BOCS, baseline | 25.3 ± 5.9 | 24.6 ± 5.7 | 24.8 ± 6.8 | 27.2 ± 5.7 | ns |
Y-BOCS,% decrease, LOCF | 34 ± 27 | 41 ± 31 | 38 ± 20 | 17 ± 21 | ns |
Y-BOCS,% decrease, completersa | 44 ± 26 n = 24 | 51 ± 24 n = 14 | 56 ± 10 n = 4 | 22 ± 25 n = 6 | F: 4.1 (2, 21)* |
MADRS, baseline | 12.2 ± 7.8 | 10.2 ± 6.4 | 8.4 ± 3.6 | 19.9 ± 8.7 | F: 8.6 (2, 33)*** |
MADRS, endpoint, LOCF | 8.3 ± 6.8 | 5.8 ± 5.6 | 9.3 ± 8.1 | 12.1 ± 6.2 | ns |
Premature discontinuation, n (%)b | 12 (33) | 4 (22) (4, 8, 8, 10 w) | 5 (56) (1, 2, 8, 10, 10 w) | 3 (33) (10, 10, 10 w) | ns |
PGE, 1 or 2 at endpoint, n (%) | 18 (50) | 11 (61) | 5 (56) | 2 (22) | ns |
Responders, n (%) | 17 (47) | 11 (61) | 5 (56) | 1 (11) | χ2: 6.4 (2)* |